{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T00:51:56Z","timestamp":1781830316792,"version":"3.54.5"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T00:00:00Z","timestamp":1777075200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T00:00:00Z","timestamp":1781827200000},"content-version":"vor","delay-in-days":55,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-50128-7","type":"journal-article","created":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T08:26:51Z","timestamp":1777105611000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Profiling the tumor immunological status in Japanese solid cancers using the tumor immune status scoring algorithm"],"prefix":"10.1038","volume":"16","author":[{"given":"Tomoatsu","family":"Ikeya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasufumi","family":"Kikuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadashi","family":"Ashizawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akari","family":"Kanematsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chie","family":"Maeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Iizuka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazue","family":"Yamashita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruo","family":"Miyata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Nagashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichi","family":"Urakami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuji","family":"Shimoda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiichi","family":"Ohshima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Muramatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Sugino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akio","family":"Shiomi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhisa","family":"Ohde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Etsuro","family":"Bando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teiichi","family":"Sugiura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Mukaigawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seiichiro","family":"Nishimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirotsugu","family":"Kenmotsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3813-7726","authenticated-orcid":false,"given":"Yasuto","family":"Akiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,25]]},"reference":[{"issue":"4","key":"50128_CR1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-006454","volume":"11","author":"J Jung","year":"2023","unstructured":"Jung, J., Heo, Y. J. & Park, S. High tumor mutational burden predicts favorable response to anti-PD-(L)1 therapy in patients with solid tumor: A real-world pan-tumor analysis. J. Immunother. Cancer. 11(4), e006454 (2023).","journal-title":"J. Immunother. Cancer."},{"issue":"21","key":"50128_CR2","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","volume":"372","author":"EB Garon","year":"2015","unstructured":"Garon, E. B. et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N. Engl. J. Med. 372(21), 2018\u20132028 (2015).","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"50128_CR3","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1038\/s41568-020-0285-7","volume":"20","author":"D Bruni","year":"2020","unstructured":"Bruni, D., Angell, H. K. & Galon, J. The immune contexture and immunoscore in cancer prognosis and therapeutic efficacy. Nat. Rev. Cancer. 20(11), 662\u2013680 (2020).","journal-title":"Nat. Rev. Cancer."},{"key":"50128_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2022.101367","volume":"18","author":"C Ren","year":"2022","unstructured":"Ren, C., Li, J., Zhou, Y., Zhang, S. & Wang, Q. Typical tumor immune microenvironment status determine prognosis in lung adenocarcinoma. Transl. Oncol. 18, 101367 (2022).","journal-title":"Transl. Oncol."},{"issue":"1","key":"50128_CR5","volume":"7","author":"L Zhang","year":"2024","unstructured":"Zhang, L. et al. Tumor-infiltrating immune cell score as an independent prognostic predictor for endometrial carcinoma: Insights from a comprehensive analysis of the immune landscape. Cancer. Rep. 7(1), e1939 (2024).","journal-title":"Cancer. Rep."},{"issue":"11","key":"50128_CR6","doi-asserted-by":"publisher","first-page":"2076","DOI":"10.1158\/0008-5472.CAN-21-2542","volume":"82","author":"N Sinha","year":"2022","unstructured":"Sinha, N. et al. Immune determinants of the association between tumor mutational burden and immunotherapy response across cancer types. Cancer. Res. 82(11), 2076\u20132083 (2022).","journal-title":"Cancer. Res."},{"issue":"25","key":"50128_CR7","doi-asserted-by":"publisher","first-page":"2500","DOI":"10.1056\/NEJMc1713444","volume":"377","author":"M Yarchoan","year":"2017","unstructured":"Yarchoan, M., Hopkins, A. & Jaffee, E. M. Tumor mutational burden and response rate to PD-1 inhibition. N. Engl. J. Med. 377(25), 2500\u20132501 (2017).","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"50128_CR8","doi-asserted-by":"publisher","first-page":"2139","DOI":"10.1158\/0008-5472.CAN-15-0255","volume":"75","author":"MWL Teng","year":"2015","unstructured":"Teng, M. W. L., Ngiow, S. F., Ribas, A. & Smyth, M. J. Classifying cancers based on T-cell infiltration and PD-L1. Cancer. Res. 75(11), 2139\u20132145 (2015).","journal-title":"Cancer. Res."},{"issue":"9","key":"50128_CR9","doi-asserted-by":"publisher","first-page":"2261","DOI":"10.1158\/1078-0432.CCR-15-2834","volume":"22","author":"CY Ock","year":"2016","unstructured":"Ock, C. Y. et al. Pan-cancer immunogenomic perspective on the tumor microenvironment based on PD-L1 and CD8 T-cell infiltration. Clin. Cancer. Res. 22(9), 2261\u20132270 (2016).","journal-title":"Clin. Cancer. Res."},{"issue":"1","key":"50128_CR10","first-page":"219","volume":"54","author":"R Kondou","year":"2019","unstructured":"Kondou, R. et al. Classification of tumor microenvironment immune types based on immune response-associated gene expression. Int. J. Oncol. 54(1), 219\u2013228 (2019).","journal-title":"Int. J. Oncol."},{"issue":"5","key":"50128_CR11","doi-asserted-by":"publisher","first-page":"232","DOI":"10.3892\/mco.2021.2395","volume":"15","author":"R Kondou","year":"2021","unstructured":"Kondou, R. et al. Identification of tumor microenvironment-associated immunological genes as potent prognostic markers in the cancer genome analysis project HOPE. Mol. Clin. Oncol. 15(5), 232 (2021).","journal-title":"Mol. Clin. Oncol."},{"key":"50128_CR12","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.960579","volume":"12","author":"Y Liu","year":"2023","unstructured":"Liu, Y. et al. Identification of a tumor immune-inflammation signature predicting prognosis and immune status in breast cancer. Front. Oncol. 12, 060579 (2023).","journal-title":"Front. Oncol."},{"issue":"8","key":"50128_CR13","doi-asserted-by":"publisher","first-page":"2930","DOI":"10.1172\/JCI91190","volume":"127","author":"M Ayers","year":"2017","unstructured":"Ayers, M. et al. INF- \u03b3 -related mRNA profile predicts clinical response to PD-1 blockade. J. Clin. Invest. 127(8), 2930\u20132940 (2017).","journal-title":"J. Clin. Invest."},{"issue":"13","key":"50128_CR14","doi-asserted-by":"publisher","first-page":"3540","DOI":"10.1158\/0008-5472.CAN-16-3556","volume":"77","author":"A Prat","year":"2017","unstructured":"Prat, A. et al. Immune-related gene expression profiling after PD-1 blockade in non-small cell lung carcinoma, head and neck squamous cell carcinoma, and melanoma. Cancer. Res. 77(13), 3540\u20133550 (2017).","journal-title":"Cancer. Res."},{"key":"50128_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2023.104452","volume":"88","author":"A Mezheyeuski","year":"2013","unstructured":"Mezheyeuski, A. et al. An immune score reflecting pro-and anti-tumoral balance of tumor microenvironment has major prognostic impact and predicts immunotherapy response in solid cancers. EBioMedicine 88, 104452 (2013).","journal-title":"EBioMedicine"},{"issue":"1","key":"50128_CR16","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1186\/s40478-024-01895-9","volume":"12","author":"G Xiao","year":"2024","unstructured":"Xiao, G. et al. An immune scoring system predicts prognosis and immune characteristics in lung adenocarcinoma brain metastases by RNA sequencing. Acta. Neuropathol. Commun. 12(1), 181 (2024).","journal-title":"Acta. Neuropathol. Commun."},{"issue":"10","key":"50128_CR17","doi-asserted-by":"publisher","first-page":"4315","DOI":"10.21873\/anticanres.17782","volume":"45","author":"T Ikeya","year":"2025","unstructured":"Ikeya, T. et al. Pancancer landscape of long non-coding RNA expression and immune status of the tumor microenvironment in Japanese cancer patients. Anticancer. Res. 45(10), 4315\u20134331 (2025).","journal-title":"Anticancer. Res."},{"issue":"11","key":"50128_CR18","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1038\/nm.3967","volume":"21","author":"J Guinney","year":"2015","unstructured":"Guinney, J. et al. The consensus molecular subtypes of colorectal cancer. Nat. Med. 21(11), 1350\u20131356 (2015).","journal-title":"Nat. Med."},{"issue":"7","key":"50128_CR19","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1016\/j.jtho.2023.03.012","volume":"18","author":"D Sun","year":"2023","unstructured":"Sun, D. et al. Classification of tumor immune microenvironment according to programmed death-ligand 1 expression and immune infiltration predicts response to immunotherapy plus chemotherapy in advanced patients with NSCLC. J. Thorac. Oncol. 18(7), 869\u2013881 (2023).","journal-title":"J. Thorac. Oncol."},{"issue":"5","key":"50128_CR20","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-011363","volume":"13","author":"AD Zander","year":"2025","unstructured":"Zander, A. D. et al. Development and validation of the immune profile score (IPS), a novel multiomic algorithmic assay for stratifying outcomes in a real-world cohort of patients with advanced solid cancer treated with immune checkpoint inhibitors. J. Immunother. Cancer. 13(5), e011363 (2025).","journal-title":"J. Immunother. Cancer."},{"issue":"4","key":"50128_CR21","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1016\/j.ejso.2021.10.007","volume":"48","author":"N Hodges","year":"2022","unstructured":"Hodges, N., Mackenzie, H., D`Souza, N., Brown, G. & Miskovic, D. Survival outcomes for right-versus left-sided colon cancer and rectal cancer in England: A propensity-score matched population-based cohort study. Eur. J. Surg. Oncol. 48(4), 841\u2013849 (2022).","journal-title":"Eur. J. Surg. Oncol."},{"issue":"38","key":"50128_CR22","doi-asserted-by":"publisher","first-page":"63140","DOI":"10.18632\/oncotarget.18702","volume":"8","author":"LJW Bosch","year":"2017","unstructured":"Bosch, L. J. W. et al. Decoy receptor 1 (DCR1) promoter hypermethylation and response to irinotecan in metastatic colorectal cancer. Oncotarget 8(38), 63140\u201363154 (2017).","journal-title":"Oncotarget"},{"issue":"1","key":"50128_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-14893-w","volume":"7","author":"WJ Lee","year":"2017","unstructured":"Lee, W. J. et al. Decoy Wnt receptor (SLRP6E1E2)-expressing adenovirus induces anti-fibrotic effect via inhibition of Wnt and TGF-\u03b2 signaling. Sci. Rep. 7(1), 15070 (2017).","journal-title":"Sci. Rep."},{"issue":"1","key":"50128_CR24","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1200\/JCO.23.00586","volume":"42","author":"CE Sissy","year":"2024","unstructured":"Sissy, C. E. et al. International validation of the immunoscore biopsy in patients with rectal managed by a watch-and-wait strategy. J. Clin. Oncol. 42(1), 70\u201380 (2024).","journal-title":"J. Clin. Oncol."},{"issue":"29","key":"50128_CR25","doi-asserted-by":"publisher","first-page":"3430","DOI":"10.1200\/JCO.23.02030","volume":"42","author":"CJM Williams","year":"2024","unstructured":"Williams, C. J. M. et al. Evaluation of CD3 and CD8 T-cell immunohistochemistry for prognostication and prediction of benefit from adjuvant chemotherapy in early-stage colorectal cancer within the QUASAR trial. J. Clin. Oncol. 42(29), 3430\u20133442 (2024).","journal-title":"J. Clin. Oncol."},{"issue":"7","key":"50128_CR26","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1016\/S1470-2045(22)00274-1","volume":"23","author":"C Antoniotti","year":"2022","unstructured":"Antoniotti, C. et al. Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): A multicentre, open-label, randomized, controlled, phase 2 trial. Lancet. Oncol. 23(7), 876\u2013887 (2022).","journal-title":"Lancet. Oncol."},{"issue":"25","key":"50128_CR27","doi-asserted-by":"publisher","first-page":"2363","DOI":"10.1056\/NEJMoa2201445","volume":"386","author":"A Cercek","year":"2022","unstructured":"Cercek, A. et al. PD-1 blockade in mismatch repair-deficient, locally advanced rectal cancer. N. Engl. J. Med. 386(25), 2363\u20132376 (2022).","journal-title":"N. Engl. J. Med."},{"issue":"21","key":"50128_CR28","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1056\/NEJMoa2400634","volume":"390","author":"M Chalabi","year":"2024","unstructured":"Chalabi, M. et al. Neoadjuvant immunotherapy in locally advanced mismatch repair-deficient colon cancer. N. Engl. J Med. 390(21), 1949\u20131958 (2024).","journal-title":"N. Engl. J Med."},{"issue":"21","key":"50128_CR29","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.1056\/NEJMoa2402141","volume":"391","author":"T Andre","year":"2024","unstructured":"Andre, T. et al. Nivolumab plus ipilimumab in microsatellite-instability-high metastatic colorectal cancer. N. Engl. J. Med. 391(21), 2024\u20132026 (2024).","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"50128_CR30","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1038\/s41591-020-0805-8","volume":"26","author":"M Chalabi","year":"2020","unstructured":"Chalabi, M. et al. Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers. Nat. Med. 26(4), 566\u2013576 (2020).","journal-title":"Nat. Med."},{"issue":"9","key":"50128_CR31","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1016\/j.ccell.2023.08.002","volume":"41","author":"SJ Wagner","year":"2023","unstructured":"Wagner, S. J. et al. Transformer-based biomarker prediction from colorectal cancer histology: A large-scale multicentric study. Cancer Cell 41(9), 1650\u20131661 (2023).","journal-title":"Cancer Cell"},{"key":"50128_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.oor.2025.100767","volume":"16","author":"R Bhushan","year":"2025","unstructured":"Bhushan, R. et al. The role of artificial intelligence in predicting cancer immunotherapy response. Oral. Oncol. Rep. 16, 100767 (2025).","journal-title":"Oral. Oncol. Rep."},{"issue":"5","key":"50128_CR33","doi-asserted-by":"publisher","DOI":"10.1093\/bib\/bbae410","volume":"25","author":"X Ding","year":"2024","unstructured":"Ding, X., Zhang, L., Fan, M. & Li, L. TME-NET: An interpretable deep neural network for predicting pan-cancer immune checkpoint inhibitor responses. Brief. Bioinform. 25(5), bbae410 (2024).","journal-title":"Brief. Bioinform."},{"issue":"1","key":"50128_CR34","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1038\/s41698-025-01125-y","volume":"9","author":"XJ Cai","year":"2025","unstructured":"Cai, X. J. et al. Tumor cell- and infiltrating immune cell-based supervised learning artificial intelligence multimodal platform for tumor prognosis. NPJ. Precis. Oncol. 9(1), 348 (2025).","journal-title":"NPJ. Precis. Oncol."},{"key":"50128_CR35","doi-asserted-by":"publisher","DOI":"10.1200\/CCI.24.00133","volume":"8","author":"C Sako","year":"2024","unstructured":"Sako, C. et al. Real-world and clinical trial validation of a deep learning radiomic biomarker for PD-(L)1 immune checkpoint inhibitor response in advanced non-small cell lung cancer. JCO. Clin. Cancer. Inform. 8, e2400133 (2024).","journal-title":"JCO. Clin. Cancer. Inform."},{"key":"50128_CR36","doi-asserted-by":"crossref","unstructured":"Li, J., Liang, Y.B., Wang, Q.B., Luo, W.L., Chen, X.M., Lakang, Y. et al. Rechallenge with immune checkpoint inhibitors in patients with hepatocellular carcinoma a narrative review. Liver. Cancer. (2025) (in press).","DOI":"10.1159\/000549355"},{"issue":"5","key":"50128_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2022.104228","volume":"25","author":"Y Kang","year":"2022","unstructured":"Kang, Y., Vijay, S. & Gujral, T. S. Deep neural network modeling identifies biomarkers of response to immune-checkpoint therapy. iScience. 25(5), 104228 (2022).","journal-title":"iScience."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-50128-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-50128-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-50128-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T00:05:40Z","timestamp":1781827540000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-50128-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,25]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["50128"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-50128-7","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,25]]},"assertion":[{"value":"23 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"19139"}}